Drug developers have studied pills like Jesduvroq and Vafseo as alternatives to injectable biologic drugs like Amgen’s Epogen in the hopes they ... The FDA’s initial rejection of Vafseo prompted ...
Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to ...
In 2022, NeuGen informed MassMutual they were laying off 110 employees. According to the suit, MassMutual declared a total termination of the Agreement and gave the Fund to the Plan participants at ...
Plus: A breakthrough in treating food allergies. All in The Temperature, a weekly newsletter covering climate, health and ...
“Immatics kicked off 2024 with a successful capital raise ... this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully ...